Prescription Description
| Prescription ID | TCMF5722 |
| Pinyin Name | Qing Shen Yin Chong Ji |
| Chinese Name | 清身饮冲剂 |
| English Name | Qing Shen Yin Infusion |
| Function Description | 盗汗 |
| Indications | None |
| Disease ICD-11 Category | |
| Human Tissues Associated with Indication | |
| Reference | CFDA |
| Reference Book/link | http://samr.cfda.gov.cn/WS01/CL0001/ |
Prescription Components
| Component ID | Latin Name | Chinese Name | Component Quantity | Barcode |
|---|---|---|---|---|
| TCMH1177 | Ilex cornuta | 枸骨叶 | TCMH1177 | ITSAN835-14 |
| TCMH2343 | Scrophularia ningpoensis | 玄参 | TCMH2343 | ITSAO4295-14 |
| TCMH449 | Cortex lycii radicis | 地骨皮 | TCMH449 | |
| TCMH1321 | Os draconis | 龙骨 | TCMH1321 | |
| TCMH2059 | Radix pseudostellariae | 太子参 | TCMH2059 | |
| TCMH451 | Rehmannia glutinosa | 地黄 | TCMH451 | ITSAH4578-14 |
| TCMH1594 | Oryza sativa l. var. glutinosa matsum. | 糯稻根 | TCMH1594 | |
| TCMH628 | Glycyrrhiza uralensis | 甘草 | TCMH628 | ITSAM892-14 |
Targeted Human Proteins by the Ingredients of Prescription
| Target ID | Gene Symbol | Target Name | Target Class | Uniprot ID |
|---|---|---|---|---|
| TCMT101 | PTPN1 | Protein-tyrosine phosphatase 1B | Hydrolase | P18031 |
| TCMT102 | ACP1 | Low molecular weight phosphotyrosine protein phosphatase | Hydrolase | P24666 |
| TCMT103 | PTPRF | Receptor-type tyrosine-protein phosphatase F (LAR) | Hydrolase | P10586 |
| TCMT112 | ADORA3 | Adenosine A3 receptor | GPCR | P0DMS8 |
| TCMT127 | PARP1 | Poly [ADP-ribose] polymerase-1 | Transferase | P09874 |
| TCMT128 | TNKS2 | Tankyrase-2 | Transferase | Q9H2K2 |
| TCMT129 | TNKS | Tankyrase-1 | Transferase | O95271 |
| TCMT131 | ACHE | Acetylcholinesterase | Hydrolase | P22303 |
| TCMT133 | CA1 | Carbonic anhydrase I | Lyase | P00915 |
| TCMT134 | CA2 | Carbonic anhydrase II | Lyase | P00918 |
| TCMT135 | CA14 | Carbonic anhydrase XIV | Lyase | Q9ULX7 |
| TCMT136 | CA12 | Carbonic anhydrase XII | Lyase | O43570 |
| TCMT138 | CA7 | Carbonic anhydrase VII | Lyase | P43166 |
| TCMT142 | CA4 | Carbonic anhydrase IV | Lyase | P22748 |
| TCMT150 | RORC | Nuclear receptor ROR-gamma | Nuclear receptor | P51449 |
| TCMT156 | CYP19A1 | Cytochrome P450 19A1 | Oxidoreductase | P11511 |
| TCMT159 | TYR | Tyrosinase | Oxidoreductase | P14679 |
| TCMT162 | UGT1A1 | UDP-glucuronosyltransferase 1-1 | Transferase | P22309 |
| TCMT174 | HSD11B1 | 11-beta-hydroxysteroid dehydrogenase 1 | Oxidoreductase | P28845 |
| TCMT190 | PTPN2 | T-cell protein-tyrosine phosphatase | Hydrolase | P17706 |
| TCMT209 | HSD11B2 | 11-beta-hydroxysteroid dehydrogenase 2 | Oxidoreductase | P80365 |
| TCMT215 | CYP1A1 | Cytochrome P450 1A1 | Oxidoreductase | P04798 |
| TCMT219 | CYP1A2 | Cytochrome P450 1A2 | Oxidoreductase | P05177 |
| TCMT223 | AKR1B1 | Aldose reductase | Oxidoreductase | P15121 |
| TCMT23 | ALPL | Alkaline phosphatase, tissue-nonspecific isozyme | Hydrolase | P05186 |
| TCMT231 | GBA2 | Beta-glucosidase | Hydrolase | Q9HCG7 |
| TCMT236 | ESR2 | Estrogen receptor beta | Nuclear receptor | Q92731 |
| TCMT249 | CDK6 | Cyclin-dependent kinase 6 | Kinase | Q00534 |
| TCMT257 | CYP1B1 | Cytochrome P450 1B1 | Oxidoreductase | Q16678 |
| TCMT261 | DAPK1 | Death-associated protein kinase 1 | Kinase | P53355 |
| TCMT280 | AKR1B10 | Aldo-keto reductase family 1 member B10 | Oxidoreductase | O60218 |
| TCMT296 | ADORA1 | Adenosine A1 receptor | GPCR | P30542 |
| TCMT297 | FABP4 | Fatty acid binding protein adipocyte | Unclassified | P15090 |
| TCMT298 | FABP3 | Fatty acid binding protein muscle | Hydrolase | P05413 |
| TCMT344 | AOX1 | Aldehyde oxidase | Oxidoreductase | Q06278 |
| TCMT46 | F3 | Coagulation factor III | Unclassified | P13726 |
| TCMT47 | BCL2 | Apoptosis regulator Bcl-2 | Ion channel | P10415 |
| TCMT506 | PTK2B | Protein tyrosine kinase 2 beta | Kinase | Q14289 |
| TCMT563 | CDC25B | Dual specificity phosphatase Cdc25B | Hydrolase | P30305 |
| TCMT591 | ESRRA | Estrogen-related receptor alpha | Nuclear receptor | P11474 |
| TCMT592 | XDH | Xanthine dehydrogenase | Oxidoreductase | P47989 |
| TCMT597 | SLC28A3 | Solute carrier family 28 member 3 | Transporter | Q9HAS3 |
| TCMT614 | EGLN1 | Egl nine homolog 1 | Oxidoreductase | Q9GZT9 |
| TCMT63 | PPARA | Peroxisome proliferator-activated receptor alpha | Nuclear receptor | Q07869 |
| TCMT65 | HSD17B1 | Estradiol 17-beta-dehydrogenase 1 | Oxidoreductase | P14061 |
| TCMT66 | HSD17B2 | Estradiol 17-beta-dehydrogenase 2 | Oxidoreductase | P37059 |
| TCMT709 | SLC28A2 | Sodium/nucleoside cotransporter 2 | Transporter | O43868 |
| TCMT710 | SLC28A1 | Sodium/nucleoside cotransporter 1 | Transporter | O00337 |
| TCMT752 | CSNK2A1 | Casein kinase II alpha | Kinase | P68400 |
| TCMT808 | FABP5 | Fatty acid binding protein epidermal | Unclassified | Q01469 |
| TCMT809 | FABP2 | Fatty acid binding protein intestinal | Unclassified | P12104 |
| TCMT810 | TLR2 | Toll-like receptor 2 | Unclassified | O60603 |
| TCMT82 | ESR1 | Estrogen receptor alpha | Nuclear receptor | P03372 |
| TCMT822 | FUT7 | Alpha-(1,3)-fucosyltransferase 7 | Transferase | Q11130 |
| TCMT907 | FDPS | Farnesyl diphosphate synthase | Lyase | P14324 |
| TCMT910 | ESRRB | Estrogen-related receptor beta | Nuclear receptor | O95718 |
Targeted Pathogenic Microbes by the Ingredients of Prescription
| Target ID | Target Name |
|---|---|
| TCMT1170 | Enterobacter cloacae |
| TCMT1175 | Human immunodeficiency virus |
| TCMT1176 | Streptococcus pneumoniae |
| TCMT1178 | Actinomyces viscosus |
| TCMT1179 | Escherichia coli ATCC 8739 |
| TCMT1181 | Mycobacterium tuberculosis H37Ra |
| TCMT1186 | Plasmodium yoelii yoelii |
| TCMT1209 | Staphylococcus haemolyticus |
| TCMT1212 | Verticillium dahliae |
| TCMT1214 | Enterococcus faecium |
| TCMT1215 | Pseudomonas aeruginosa PAO1 |
| TCMT1218 | Staphylococcus aureus |
| TCMT1223 | Staphylococcus epidermidis |
| TCMT1224 | Proteus mirabilis |
| TCMT1226 | Klebsiella pneumoniae |
| TCMT1227 | Streptococcus |
| TCMT1229 | Enterococcus faecalis |
| TCMT1232 | Pseudomonas aeruginosa |
| TCMT1234 | Bacillus coagulans |
| TCMT1235 | Clostridium sporogenes |
| TCMT1236 | Mycobacterium bovis |
| TCMT1237 | Mycobacterium kansasii |
| TCMT1238 | Mycobacterium xenopi |
| TCMT1239 | Mycobacterium marinum |
| TCMT1243 | Aspergillus flavus |
| TCMT1246 | Escherichia coli |
| TCMT1248 | Hepatitis C virus |
| TCMT1249 | Dengue virus 2 |
| TCMT1251 | Candida albicans |
| TCMT1253 | Penicillium chrysogenum |
| TCMT1255 | Human immunodeficiency virus 1 |
| TCMT1284 | Penicillium expansum |
| TCMT1286 | Bacillus cereus |
| TCMT1294 | Human parainfluenza virus 3 |
| TCMT1346 | Helicobacter pylori |
| TCMT1349 | Helicobacter pylori SS1 |
| TCMT1361 | Neisseria meningitidis |
| TCMT1382 | Plasmodium falciparum (isolate K1 / Thailand) |
| TCMT1412 | Salmonella typhimurium |
| TCMT1438 | Plasmodium falciparum |
| TCMT1439 | Mycobacterium smegmatis |
| TCMT1442 | Leishmania donovani |
| TCMT1443 | Leishmania amazonensis |
| TCMT1447 | Respiratory syncytial virus |
| TCMT1448 | Enterobacter aerogenes |
| TCMT1449 | Influenza A virus |
| TCMT1450 | Plasmodium falciparum 3D7 |
| TCMT1454 | Bacillus subtilis |
| TCMT1455 | Mycobacterium tuberculosis H37Rv |
| TCMT1457 | Leishmania major |
| TCMT1458 | Filobasidiella neoformans |
| TCMT1462 | Streptococcus mutans |
| TCMT1463 | Mycobacterium tuberculosis |
| TCMT1464 | Hepatitis B virus |
| TCMT1465 | Entamoeba histolytica |
Gene Ontology Associated to Targeted Human Proteins
| GO Term | GO Name | Enriched Genes | Log10 Adjusted P-value |
|---|---|---|---|
| [BP] GO:0008202 | steroid metabolic process | AKR1B1, AKR1B10, CYP19A1, CYP1A1, CYP1A2, CYP1B1, ESR1, FDPS, GBA2, HSD11B1, HSD11B2, HSD17B1, HSD17B2 | 10.1474 |
| [BP] GO:0006629 | lipid metabolic process | ACHE, ADORA1, AKR1B1, AKR1B10, CSNK2A1, CYP19A1, CYP1A1, CYP1A2, CYP1B1, ESR1, FABP3, FABP4, FDPS, FUT7, GBA2, HSD11B1, HSD11B2, HSD17B1, HSD17B2, PPARA | 9.13302 |
| [BP] GO:0042445 | hormone metabolic process | ACHE, AKR1B1, CYP19A1, CYP1A1, CYP1B1, ESR1, HSD11B1, HSD11B2, HSD17B1, HSD17B2 | 7.60216 |
| [BP] GO:0019748 | secondary metabolic process | AKR1B1, AKR1B10, BCL2, CYP1A1, CYP1A2, CYP1B1, TYR | 7.27443 |
| [BP] GO:0033993 | response to lipid | ALPL, BCL2, CA2, CDK6, CSNK2A1, CYP1A1, CYP1A2, ESR1, ESRRA, FABP3, HSD11B2, HSD17B2, RORC, TYR | 6.24329 |
| [BP] GO:0008152 | metabolic process | ACHE, ADORA1, AKR1B1, AKR1B10, ALPL, AOX1, BCL2, CA1, CA12, CA2, CA4, CA7, CDC25B, CDK6, CSNK2A1, CYP19A1, CYP1A1, CYP1A2, CYP1B1, ESR1, ESR2, ESRRA, ESRRB, F3, FABP3, FABP4, FDPS, FUT7, GBA2, HSD11B1, HSD11B2, HSD17B1, HSD17B2, PPARA, PTPN1, RORC, TNKS, TNKS2, TYR, XDH | 5.97772 |
| [BP] GO:0015701 | bicarbonate transport | CA1, CA12, CA14, CA2, CA4, CA7 | 5.97772 |
| [BP] GO:0044281 | small molecule metabolic process | AKR1B1, AKR1B10, AOX1, CA1, CA12, CA2, CA4, CA7, CYP19A1, CYP1A1, CYP1A2, CYP1B1, FABP3, FDPS, FUT7, GBA2, PPARA, TYR, XDH | 5.933 |
| [BP] GO:0034754 | cellular hormone metabolic process | AKR1B1, CYP19A1, CYP1A1, CYP1B1, ESR1, HSD17B1, HSD17B2 | 5.43265 |
| [BP] GO:0042446 | hormone biosynthetic process | AKR1B1, CYP19A1, HSD11B1, HSD11B2, HSD17B1, HSD17B2 | 5.39482 |
| [BP] GO:1901700 | response to oxygen-containing compound | AKR1B1, ALPL, BCL2, CDK6, CSNK2A1, CYP1A1, CYP1A2, CYP1B1, ESR1, ESRRA, FABP3, HSD11B2, HSD17B2, PPARA, RORC, TYR | 5.35745 |
| [BP] GO:0010817 | regulation of hormone levels | ACHE, ADORA1, AKR1B1, CYP19A1, CYP1A1, CYP1B1, ESR1, HSD11B1, HSD11B2, HSD17B1, HSD17B2 | 5.11173 |
| [BP] GO:0006694 | steroid biosynthetic process | AKR1B1, CYP19A1, FDPS, HSD11B1, HSD11B2, HSD17B1, HSD17B2 | 5.05436 |
| [BP] GO:0006730 | one-carbon metabolic process | CA1, CA12, CA2, CA4, CA7 | 4.94262 |
| [BP] GO:0014070 | response to organic cyclic compound | ALPL, BCL2, CA2, CSNK2A1, CYP1A1, CYP1A2, CYP1B1, ESR1, ESRRA, HSD11B2, RORC, TYR | 4.64836 |
| [BP] GO:0055114 | oxidation-reduction process | AKR1B1, AKR1B10, AOX1, CYP19A1, CYP1A1, CYP1A2, CYP1B1, HSD11B1, HSD11B2, HSD17B1, HSD17B2, TYR, XDH | 4.62449 |
| [BP] GO:0032847 | regulation of cellular pH reduction | BCL2, CA2, CA7 | 4.55735 |
| [BP] GO:0065008 | regulation of biological quality | ACHE, ADORA1, AKR1B1, BCL2, CA12, CA2, CA7, CDK6, CYP19A1, CYP1A1, CYP1B1, ESR1, F3, FABP3, FABP4, HSD11B1, HSD11B2, HSD17B1, HSD17B2, PPARA, TNKS, TNKS2, XDH | 4.51129 |
| [BP] GO:0010033 | response to organic substance | AKR1B1, ALPL, BCL2, CA2, CDK6, CSNK2A1, CYP1A1, CYP1A2, CYP1B1, ESR1, ESRRA, FABP3, FABP4, HSD11B2, HSD17B2, PPARA, RORC, TYR | 4.43982 |
| [BP] GO:0016042 | lipid catabolic process | ADORA1, AKR1B10, CYP19A1, CYP1A2, CYP1B1, FABP3, FABP4, GBA2 | 4.16868 |
| [BP] GO:0048513 | animal organ development | ACHE, BCL2, CA2, CSNK2A1, CYP19A1, CYP1A1, CYP1A2, ESR1, ESRRA, ESRRB, HSD11B1, HSD17B2, PPARA, TYR | 4.1601 |
| [BP] GO:0009725 | response to hormone | AKR1B1, ALPL, BCL2, CA2, CSNK2A1, CYP1A2, ESR1, ESRRA, FABP3, HSD11B2, PPARA | 4.1601 |
| [BP] GO:0044237 | cellular metabolic process | ACHE, AKR1B1, AKR1B10, ALPL, AOX1, BCL2, CA1, CA12, CA2, CA4, CA7, CDC25B, CDK6, CSNK2A1, CYP19A1, CYP1A1, CYP1A2, CYP1B1, ESR1, ESR2, ESRRA, ESRRB, FABP3, FABP4, FDPS, FUT7, GBA2, HSD17B1, HSD17B2, PPARA, PTPN1, RORC, TNKS, TNKS2, TYR, XDH | 4.04812 |
| [BP] GO:0008210 | estrogen metabolic process | CYP19A1, CYP1B1, HSD17B1, HSD17B2 | 3.96579 |
| [BP] GO:1901615 | organic hydroxy compound metabolic process | AKR1B1, AKR1B10, BCL2, CYP19A1, CYP1A1, CYP1B1, FDPS, GBA2, TYR | 3.96151 |
| [BP] GO:0008610 | lipid biosynthetic process | ACHE, AKR1B1, CSNK2A1, CYP19A1, CYP1A1, FDPS, HSD11B1, HSD11B2, HSD17B1, HSD17B2 | 3.95317 |
| [BP] GO:0043401 | steroid hormone mediated signaling pathway | ESR1, ESR2, ESRRA, ESRRB, PPARA, RORC | 3.77351 |
| [BP] GO:0044255 | cellular lipid metabolic process | ACHE, AKR1B10, CSNK2A1, CYP1A1, CYP1A2, CYP1B1, FABP3, FABP4, FDPS, FUT7, GBA2, PPARA | 3.55768 |
| [BP] GO:0048856 | anatomical structure development | ACHE, ADORA1, AKR1B1, ALPL, BCL2, CA2, CDK6, CSNK2A1, CYP19A1, CYP1A1, CYP1A2, CYP1B1, ESR1, ESRRA, ESRRB, GBA2, HSD11B1, HSD17B2, PPARA, RORC, TYR | 3.55768 |
| [BP] GO:0044238 | primary metabolic process | ACHE, ADORA1, AKR1B1, AKR1B10, ALPL, AOX1, BCL2, CDC25B, CDK6, CSNK2A1, CYP19A1, CYP1A1, CYP1A2, CYP1B1, ESR1, ESR2, ESRRA, ESRRB, F3, FABP3, FABP4, FDPS, FUT7, GBA2, HSD11B1, HSD11B2, HSD17B1, HSD17B2, PPARA, PTPN1, RORC, TNKS, TNKS2, TYR, XDH | 3.36248 |
| [BP] GO:0097267 | omega-hydroxylase P450 pathway | CYP1A1, CYP1A2, CYP1B1 | 3.32306 |
| [BP] GO:0006367 | transcription initiation from RNA polymerase II promoter | ESR1, ESR2, ESRRA, ESRRB, PPARA, RORC | 3.31331 |
| [BP] GO:0042221 | response to chemical | AKR1B1, ALPL, BCL2, CA2, CDK6, CSNK2A1, CYP1A1, CYP1A2, CYP1B1, ESR1, ESRRA, FABP3, FABP4, HSD11B2, HSD17B2, PPARA, RORC, TYR | 3.24976 |
| [BP] GO:0009755 | hormone-mediated signaling pathway | ESR1, ESR2, ESRRA, ESRRB, PPARA, RORC | 3.22065 |
| [BP] GO:0032502 | developmental process | ACHE, ADORA1, AKR1B1, ALPL, BCL2, CA2, CDC25B, CDK6, CSNK2A1, CYP19A1, CYP1A1, CYP1A2, CYP1B1, ESR1, ESRRA, ESRRB, FABP4, FUT7, GBA2, HSD11B1, HSD17B2, PPARA, RORC, TNKS2, TYR | 3.15821 |
| [BP] GO:0030522 | intracellular receptor signaling pathway | ESR1, ESR2, ESRRA, ESRRB, PPARA, RORC | 3.12513 |
| [BP] GO:0006703 | estrogen biosynthetic process | CYP19A1, HSD17B1, HSD17B2 | 3.02735 |
| [BP] GO:0015711 | organic anion transport | CA1, CA12, CA14, CA2, CA4, CA7, FABP3, PPARA | 3.02322 |
| [BP] GO:0071704 | organic substance metabolic process | ACHE, ADORA1, AKR1B1, AKR1B10, ALPL, AOX1, BCL2, CDC25B, CDK6, CSNK2A1, CYP19A1, CYP1A1, CYP1A2, CYP1B1, ESR1, ESR2, ESRRA, ESRRB, F3, FABP3, FABP4, FDPS, FUT7, GBA2, HSD11B1, HSD11B2, HSD17B1, HSD17B2, PPARA, PTPN1, RORC, TNKS, TNKS2, TYR, XDH | 2.98826 |
| [BP] GO:0006721 | terpenoid metabolic process | AKR1B10, CYP1A1, CYP1A2, CYP1B1, FDPS | 2.94622 |
| [BP] GO:0009115 | None | AOX1, XDH | 2.84292 |
| [BP] GO:0006352 | DNA-templated transcription, initiation | ESR1, ESR2, ESRRA, ESRRB, PPARA, RORC | 2.80856 |
| [BP] GO:0009719 | response to endogenous stimulus | AKR1B1, ALPL, BCL2, CA2, CSNK2A1, CYP1A2, ESR1, ESRRA, FABP3, HSD11B2, PPARA | 2.75849 |
| [BP] GO:0006720 | isoprenoid metabolic process | AKR1B10, CYP1A1, CYP1A2, CYP1B1, FDPS | 2.65885 |
| [BP] GO:0016137 | None | AKR1B1, AKR1B10, GBA2 | 2.64904 |
| [BP] GO:0019373 | epoxygenase P450 pathway | CYP1A1, CYP1A2, CYP1B1 | 2.45044 |
| [BP] GO:0046110 | None | AOX1, XDH | 2.41339 |
| [BP] GO:0032849 | positive regulation of cellular pH reduction | CA2, CA7 | 2.41339 |
| [BP] GO:1901360 | None | ACHE, AKR1B1, AKR1B10, AOX1, BCL2, CSNK2A1, CYP19A1, CYP1A1, CYP1A2, CYP1B1, ESR1, ESR2, ESRRA, ESRRB, FDPS, GBA2, HSD11B1, HSD11B2, HSD17B1, HSD17B2, PPARA, RORC, TYR, XDH | 2.37925 |
| [BP] GO:1901575 | None | ACHE, ADORA1, AKR1B10, AOX1, CYP19A1, CYP1A1, CYP1A2, CYP1B1, FABP3, FABP4, FUT7, GBA2, XDH | 2.35885 |
| [BP] GO:0009404 | toxin metabolic process | CYP1A1, CYP1A2, CYP1B1 | 2.35506 |
| [BP] GO:1903409 | reactive oxygen species biosynthetic process | CYP1A1, CYP1A2, CYP1B1 | 2.30305 |
| [BP] GO:0009056 | catabolic process | ACHE, ADORA1, AKR1B10, AOX1, CSNK2A1, CYP19A1, CYP1A1, CYP1A2, CYP1B1, FABP3, FABP4, FUT7, GBA2, XDH | 2.30015 |
| [BP] GO:0006820 | anion transport | CA1, CA12, CA14, CA2, CA4, CA7, FABP3, PPARA | 2.30015 |
| [BP] GO:0048522 | positive regulation of cellular process | ACHE, ADORA1, AKR1B1, BCL2, CA2, CA7, CDC25B, CDK6, CSNK2A1, CYP19A1, CYP1A1, CYP1B1, ESR1, ESR2, ESRRA, ESRRB, F3, FABP3, PPARA, PTPN1, RORC, TNKS, TNKS2, XDH | 2.28414 |
| [BP] GO:0022900 | electron transport chain | AKR1B1, AOX1, CYP19A1, CYP1A2, XDH | 2.18958 |
| [BP] GO:0042127 | regulation of cell proliferation | ADORA1, ADORA3, AKR1B1, BCL2, CDC25B, CDK6, CSNK2A1, CYP1B1, ESR1, ESRRA, F3, FABP3, XDH | 2.18466 |
| [BP] GO:0070213 | None | TNKS, TNKS2 | 2.18466 |
| [BP] GO:0006145 | None | AOX1, XDH | 2.18466 |
| [BP] GO:0018894 | dibenzo-p-dioxin metabolic process | CYP1A1, CYP1A2 | 2.18466 |
| [BP] GO:0010647 | positive regulation of cell communication | ADORA1, AKR1B1, BCL2, CA2, CA7, CSNK2A1, CYP19A1, CYP1B1, F3, PTPN1, TNKS, TNKS2, XDH | 2.15862 |
| [BP] GO:0023056 | positive regulation of signaling | ADORA1, AKR1B1, BCL2, CA2, CA7, CSNK2A1, CYP19A1, CYP1B1, F3, PTPN1, TNKS, TNKS2, XDH | 2.14381 |
| [BP] GO:0044242 | None | AKR1B10, CYP1B1, FABP3, FABP4, GBA2 | 2.09102 |
| [BP] GO:0035265 | organ growth | BCL2, CYP19A1, ESR1 | 2.07314 |
| [BP] GO:0009611 | response to wounding | ACHE, ADORA3, BCL2, CYP1A1, PPARA | 2.02934 |
| [BP] GO:0032228 | regulation of synaptic transmission, GABAergic | ADORA1, CA2, CA7 | 2.00394 |
| [BP] GO:0043696 | None | CDK6, ESRRB | 2.00394 |
| [BP] GO:0043697 | None | CDK6, ESRRB | 2.00394 |
| [CC] GO:0005789 | endoplasmic reticulum membrane | BCL2, CYP19A1, CYP1A1, CYP1A2, CYP1B1, GBA2, HSD11B1, HSD11B2, HSD17B2 | 1.61402 |
| [CC] GO:0044444 | cytoplasmic part | ACHE, ADORA1, AKR1B1, AKR1B10, AOX1, BCL2, CA1, CA2, CA4, CA7, CDC25B, CDK6, CSNK2A1, CYP19A1, CYP1A1, CYP1A2, CYP1B1, ESR1, ESR2, FABP3, FABP4, FDPS, FUT7, GBA2, HSD11B1, HSD11B2, HSD17B1, HSD17B2, PTPN1, TNKS, TNKS2, TYR, XDH | 1.60306 |
| [CC] GO:0043227 | membrane-bounded organelle | ACHE, ADORA1, AKR1B1, AKR1B10, ALPL, AOX1, BCL2, CA1, CA2, CA4, CDK6, CSNK2A1, CYP19A1, CYP1A1, CYP1A2, CYP1B1, ESR1, ESR2, ESRRA, ESRRB, F3, FABP3, FABP4, FDPS, FUT7, GBA2, PPARA, PTPN1, RORC, TNKS, TNKS2, TYR, XDH | 1.3178 |
| [CC] GO:0044432 | endoplasmic reticulum part | BCL2, CYP19A1, CYP1A1, CYP1A2, CYP1B1, GBA2, HSD11B1, HSD11B2, HSD17B2, PTPN1 | 1.27183 |
| [CC] GO:0000242 | None | TNKS, TNKS2 | 0.985128 |
| [MF] GO:0046914 | transition metal ion binding | AOX1, CA1, CA12, CA2, CA4, CA7, CYP19A1, CYP1A1, CYP1A2, CYP1B1, ESR1, ESR2, ESRRA, ESRRB, PPARA, PTPN1, RORC, TNKS, TYR, XDH | 9.95659 |
| [MF] GO:0004089 | carbonate dehydratase activity | CA1, CA12, CA14, CA2, CA4, CA7 | 8.70897 |
| [MF] GO:0016614 | oxidoreductase activity, acting on CH-OH group of donors | AKR1B1, AKR1B10, AOX1, HSD11B1, HSD11B2, HSD17B1, HSD17B2, XDH | 5.97772 |
| [MF] GO:0005496 | steroid binding | ESR1, ESR2, ESRRA, ESRRB, HSD11B2, HSD17B1, RORC | 5.933 |
| [MF] GO:0098531 | transcription factor activity, direct ligand regulated sequence-specific DNA binding | ESR1, ESR2, ESRRA, ESRRB, PPARA, RORC | 5.83044 |
| [MF] GO:0004879 | nuclear receptor activity | ESR1, ESR2, ESRRA, ESRRB, PPARA, RORC | 5.83044 |
| [MF] GO:0003824 | catalytic activity | ACHE, ADORA1, AKR1B1, AKR1B10, ALPL, AOX1, CA1, CA12, CA14, CA2, CA4, CA7, CDC25B, CDK6, CSNK2A1, CYP19A1, CYP1A1, CYP1A2, CYP1B1, F3, FDPS, FUT7, GBA2, HSD11B1, HSD11B2, HSD17B1, HSD17B2, PTPN1, TNKS, TNKS2, TYR, XDH | 5.63413 |
| [MF] GO:0016836 | hydro-lyase activity | CA1, CA12, CA14, CA2, CA4, CA7 | 5.57598 |
| [MF] GO:0016491 | oxidoreductase activity | AKR1B1, AKR1B10, AOX1, CYP19A1, CYP1A1, CYP1A2, CYP1B1, HSD11B1, HSD11B2, HSD17B1, HSD17B2, TYR, XDH | 5.46545 |
| [MF] GO:0003707 | steroid hormone receptor activity | ESR1, ESR2, ESRRA, ESRRB, PPARA, RORC | 5.43839 |
| [MF] GO:0008270 | zinc ion binding | CA1, CA12, CA2, CA4, CA7, ESR1, ESR2, ESRRA, ESRRB, PPARA, PTPN1, RORC, TNKS | 5.05436 |
| [MF] GO:0016835 | carbon-oxygen lyase activity | CA1, CA12, CA14, CA2, CA4, CA7 | 4.94262 |
| [MF] GO:0043167 | ion binding | ACHE, ALPL, AOX1, CA1, CA12, CA14, CA2, CA4, CA7, CDK6, CSNK2A1, CYP19A1, CYP1A1, CYP1A2, CYP1B1, ESR1, ESR2, ESRRA, ESRRB, F3, FABP3, FABP4, FDPS, HSD17B1, PPARA, PTPN1, RORC, TNKS, TNKS2, TYR, XDH | 4.66126 |
| [MF] GO:0043169 | cation binding | ACHE, ALPL, AOX1, CA1, CA12, CA14, CA2, CA4, CA7, CYP19A1, CYP1A1, CYP1A2, CYP1B1, ESR1, ESR2, ESRRA, ESRRB, FDPS, PPARA, PTPN1, RORC, TNKS, TNKS2, TYR, XDH | 4.09035 |
| [MF] GO:0008289 | lipid binding | ESR1, ESR2, ESRRA, ESRRB, F3, FABP3, FABP4, HSD11B2, HSD17B1, PPARA, RORC | 4.07296 |
| [MF] GO:0070330 | aromatase activity | CYP19A1, CYP1A1, CYP1A2, CYP1B1 | 4.03329 |
| [MF] GO:0016616 | oxidoreductase activity, acting on the CH-OH group of donors, NAD or NADP as acceptor | AKR1B1, AKR1B10, HSD11B1, HSD11B2, HSD17B1, HSD17B2 | 3.96151 |
| [MF] GO:0016712 | oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygen | CYP19A1, CYP1A1, CYP1A2, CYP1B1 | 3.86028 |
| [MF] GO:0033764 | steroid dehydrogenase activity, acting on the CH-OH group of donors, NAD or NADP as acceptor | HSD11B1, HSD11B2, HSD17B1, HSD17B2 | 3.80109 |
| [MF] GO:0016229 | steroid dehydrogenase activity | HSD11B1, HSD11B2, HSD17B1, HSD17B2 | 3.69496 |
| [MF] GO:0046872 | metal ion binding | ALPL, AOX1, CA1, CA12, CA14, CA2, CA4, CA7, CYP19A1, CYP1A1, CYP1A2, CYP1B1, ESR1, ESR2, ESRRA, ESRRB, FDPS, PPARA, PTPN1, RORC, TNKS, TNKS2, TYR, XDH | 3.69496 |
| [MF] GO:0005506 | iron ion binding | AOX1, CYP19A1, CYP1A1, CYP1A2, CYP1B1, XDH | 3.31331 |
| [MF] GO:0004497 | monooxygenase activity | CYP19A1, CYP1A1, CYP1A2, CYP1B1, TYR | 3.14536 |
| [MF] GO:0016903 | None | AKR1B1, AKR1B10, AOX1, XDH | 3.04918 |
| [MF] GO:0019825 | oxygen binding | CYP19A1, CYP1A1, CYP1A2, CYP1B1 | 3.02735 |
| [MF] GO:0016829 | lyase activity | CA1, CA12, CA14, CA2, CA4, CA7 | 3.02735 |
| [MF] GO:0009055 | electron transfer activity | AKR1B1, AOX1, CYP19A1, CYP1A2, XDH | 2.93285 |
| [MF] GO:0038052 | RNA polymerase II transcription factor activity, estrogen-activated sequence-specific DNA binding | ESR1, ESR2 | 2.84292 |
| [MF] GO:0003845 | None | HSD11B1, HSD11B2 | 2.84292 |
| [MF] GO:0048037 | cofactor binding | AOX1, CYP19A1, CYP1A1, CYP1A2, CYP1B1, HSD11B2, HSD17B1, XDH | 2.6307 |
| [MF] GO:0016705 | oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen | CYP19A1, CYP1A1, CYP1A2, CYP1B1, TYR | 2.27686 |
| [MF] GO:0034056 | estrogen response element binding | ESR1, ESR2 | 2.18466 |
| [MF] GO:0030284 | estrogen receptor activity | ESR1, ESR2 | 2.00394 |
KEGG Pathways Associated to Targeted Human Proteins
| KEGG Pathway ID | Enriched Genes | Log10 Adjusted P-value |
|---|---|---|
| Steroid hormone biosynthesis_Homo sapiens_hsa00140 | HSD11B1, HSD11B2, HSD17B1, HSD17B2, CYP1A2, CYP1A1, CYP1B1, CYP19A1 | 10.4892 |
| Nitrogen metabolism_Homo sapiens_hsa00910 | CA12, CA1, CA2, CA4, CA7, CA14 | 10.4533 |
| Metabolic pathways_Homo sapiens_hsa01100 | FDPS, AKR1B1, TYR, GBA2, CYP19A1, HSD11B1, FUT7, AKR1B10, HSD17B1, HSD17B2, CYP1A2, CYP1A1, AOX1, ALPL, XDH | 6.3372 |
| Ovarian steroidogenesis_Homo sapiens_hsa04913 | HSD17B1, HSD17B2, CYP1A1, CYP1B1, CYP19A1 | 5.8108 |
| Tryptophan metabolism_Homo sapiens_hsa00380 | CYP1A2, CYP1A1, AOX1, CYP1B1 | 4.5455 |
| Metabolism of xenobiotics by cytochrome P450_Homo sapiens_hsa00980 | HSD11B1, CYP1A2, CYP1A1, CYP1B1 | 3.5706 |
| Chemical carcinogenesis_Homo sapiens_hsa05204 | HSD11B1, CYP1A2, CYP1A1, CYP1B1 | 3.4374 |
| Retinol metabolism_Homo sapiens_hsa00830 | CYP1A2, CYP1A1, AOX1 | 2.427 |
| PPAR signaling pathway_Homo sapiens_hsa03320 | FABP3, FABP4, PPARA | 2.3963 |
| Sphingolipid signaling pathway_Homo sapiens_hsa04071 | ADORA3, BCL2, ADORA1 | 1.8428 |
| MicroRNAs in cancer_Homo sapiens_hsa05206 | CDK6, BCL2, CYP1B1, CDC25B | 1.7049 |
| Tyrosine metabolism_Homo sapiens_hsa00350 | AOX1, TYR | 1.7991 |
| Regulation of lipolysis in adipocytes_Homo sapiens_hsa04923 | FABP4, ADORA1 | 1.4737 |
| Galactose metabolism_Homo sapiens_hsa00052 | AKR1B10, AKR1B1 | 1.8428 |
| Glycerolipid metabolism_Homo sapiens_hsa00561 | AKR1B10, AKR1B1 | 1.4532 |
| Proximal tubule bicarbonate reclamation_Homo sapiens_hsa04964 | CA2, CA4 | 2.0252 |
| Prolactin signaling pathway_Homo sapiens_hsa04917 | ESR1, ESR2 | 1.3298 |
| Pentose and glucuronate interconversions_Homo sapiens_hsa00040 | AKR1B10, AKR1B1 | 1.7991 |
| Drug metabolism - cytochrome P450_Homo sapiens_hsa00982 | CYP1A2, AOX1 | 1.3441 |
| Adherens junction_Homo sapiens_hsa04520 | PTPN1, CSNK2A1 | 1.3272 |
| Fructose and mannose metabolism_Homo sapiens_hsa00051 | AKR1B10, AKR1B1 | 1.8428 |
| AGE-RAGE signaling pathway in diabetic complications_Homo sapiens_hsa04933 | BCL2, F3 | 1.1598 |
| Small cell lung cancer_Homo sapiens_hsa05222 | CDK6, BCL2 | 1.2405 |
| Estrogen signaling pathway_Homo sapiens_hsa04915 | ESR1, ESR2 | 1.1598 |
| Cholinergic synapse_Homo sapiens_hsa04725 | ACHE, BCL2 | 1.1142 |
| NF-kappa B signaling pathway_Homo sapiens_hsa04064 | CSNK2A1, BCL2 | 1.1939 |
| Insulin resistance_Homo sapiens_hsa04931 | PTPN1, PPARA | 1.1142 |
| Measles_Homo sapiens_hsa05162 | CDK6, CSNK2A1 | 0.994 |
| Hepatitis B_Homo sapiens_hsa05161 | CDK6, BCL2 | 0.9642 |
| Cell cycle_Homo sapiens_hsa04110 | CDK6, CDC25B | 1.0397 |
| Jak-STAT signaling pathway_Homo sapiens_hsa04630 | BCL2, AOX1 | 0.9147 |
| cGMP-PKG signaling pathway_Homo sapiens_hsa04022 | ADORA3, ADORA1 | 0.8959 |
| Epstein-Barr virus infection_Homo sapiens_hsa05169 | CSNK2A1, BCL2 | 0.8348 |
| cAMP signaling pathway_Homo sapiens_hsa04024 | ADORA1, PPARA | 0.8365 |
| Neuroactive ligand-receptor interaction_Homo sapiens_hsa04080 | ADORA3, ADORA1 | 0.6731 |
| PI3K-Akt signaling pathway_Homo sapiens_hsa04151 | CDK6, BCL2 | 0.6295 |
| Pathways in cancer_Homo sapiens_hsa05200 | CDK6, BCL2 | 0.5884 |
| Glioma_Homo sapiens_hsa05214 | CDK6 | 0.6592 |
| Prostate cancer_Homo sapiens_hsa05215 | BCL2 | 0.6148 |
| Progesterone-mediated oocyte maturation_Homo sapiens_hsa04914 | CDC25B | 0.6012 |
| Non-small cell lung cancer_Homo sapiens_hsa05223 | CDK6 | 0.6786 |
| Colorectal cancer_Homo sapiens_hsa05210 | BCL2 | 0.6592 |
| Chronic myeloid leukemia_Homo sapiens_hsa05220 | CDK6 | 0.6556 |
| Pancreatic cancer_Homo sapiens_hsa05212 | CDK6 | 0.6592 |
| Melanogenesis_Homo sapiens_hsa04916 | TYR | 0.6012 |
| Melanoma_Homo sapiens_hsa05218 | CDK6 | 0.6586 |
| Apoptosis_Homo sapiens_hsa04210 | BCL2 | 0.5302 |
| Renin secretion_Homo sapiens_hsa04924 | ADORA1 | 0.6592 |
| Morphine addiction_Homo sapiens_hsa05032 | ADORA1 | 0.6121 |
| Glucagon signaling pathway_Homo sapiens_hsa04922 | PPARA | 0.6012 |
| Ribosome biogenesis in eukaryotes_Homo sapiens_hsa03008 | CSNK2A1 | 0.6148 |
| Gastric acid secretion_Homo sapiens_hsa04971 | CA2 | 0.6556 |
| HIF-1 signaling pathway_Homo sapiens_hsa04066 | BCL2 | 0.5993 |
| Insulin signaling pathway_Homo sapiens_hsa04910 | PTPN1 | 0.5302 |
| Hepatitis C_Homo sapiens_hsa05160 | PPARA | 0.5302 |
| Thyroid hormone signaling pathway_Homo sapiens_hsa04919 | ESR1 | 0.5635 |
| Neurotrophin signaling pathway_Homo sapiens_hsa04722 | BCL2 | 0.5626 |
| Adipocytokine signaling pathway_Homo sapiens_hsa04920 | PPARA | 0.6586 |
| Glycerophospholipid metabolism_Homo sapiens_hsa00564 | ACHE | 0.6033 |
| Protein processing in endoplasmic reticulum_Homo sapiens_hsa04141 | BCL2 | 0.481 |
| Tight junction_Homo sapiens_hsa04530 | CSNK2A1 | 0.5302 |
| Signaling pathways regulating pluripotency of stem cells_Homo sapiens_hsa04550 | ESRRB | 0.5302 |
| Toxoplasmosis_Homo sapiens_hsa05145 | BCL2 | 0.5635 |
| Non-alcoholic fatty liver disease (NAFLD)_Homo sapiens_hsa04932 | PPARA | 0.5173 |
| Wnt signaling pathway_Homo sapiens_hsa04310 | CSNK2A1 | 0.5302 |
| Adrenergic signaling in cardiomyocytes_Homo sapiens_hsa04261 | BCL2 | 0.5198 |
| Pancreatic secretion_Homo sapiens_hsa04972 | CA2 | 0.6033 |
| MAPK signaling pathway_Homo sapiens_hsa04010 | CDC25B | 0.376 |
| Influenza A_Homo sapiens_hsa05164 | FDPS | 0.4766 |
| Purine metabolism_Homo sapiens_hsa00230 | XDH | 0.4766 |
| HTLV-I infection_Homo sapiens_hsa05166 | FDPS | 0.376 |
| Inflammatory bowel disease (IBD)_Homo sapiens_hsa05321 | RORC | 0.6592 |
| Focal adhesion_Homo sapiens_hsa04510 | BCL2 | 0.445 |
| Proteoglycans in cancer_Homo sapiens_hsa05205 | ESR1 | 0.445 |
| Viral carcinogenesis_Homo sapiens_hsa05203 | CDK6 | 0.445 |
| Herpes simplex infection_Homo sapiens_hsa05168 | CSNK2A1 | 0.4675 |
| p53 signaling pathway_Homo sapiens_hsa04115 | CDK6 | 0.6586 |
| Tuberculosis_Homo sapiens_hsa05152 | BCL2 | 0.4766 |
| Peroxisome_Homo sapiens_hsa04146 | XDH | 0.6295 |
| Complement and coagulation cascades_Homo sapiens_hsa04610 | F3 | 0.6362 |
| Bile secretion_Homo sapiens_hsa04976 | CA2 | 0.6586 |
| Endocrine and other factor-regulated calcium reabsorption_Homo sapiens_hsa04961 | ESR1 | 0.7251 |
| Amyotrophic lateral sclerosis (ALS)_Homo sapiens_hsa05014 | BCL2 | 0.7086 |
| Valine, leucine and isoleucine degradation_Homo sapiens_hsa00280 | AOX1 | 0.7251 |
| Drug metabolism - other enzymes_Homo sapiens_hsa00983 | XDH | 0.7251 |
| Sphingolipid metabolism_Homo sapiens_hsa00600 | GBA2 | 0.7251 |
| Aldosterone-regulated sodium reabsorption_Homo sapiens_hsa04960 | HSD11B2 | 0.7749 |
| Caffeine metabolism_Homo sapiens_hsa00232 | CYP1A2, XDH | 3.2796 |
| Linoleic acid metabolism_Homo sapiens_hsa00591 | CYP1A2 | 0.8492 |
| Other types of O-glycan biosynthesis_Homo sapiens_hsa00514 | FUT7 | 0.8419 |
| Nicotinate and nicotinamide metabolism_Homo sapiens_hsa00760 | AOX1 | 0.8492 |
| Glycosphingolipid biosynthesis - lacto and neolacto series_Homo sapiens_hsa00601 | FUT7 | 0.8623 |
| Circadian rhythm_Homo sapiens_hsa04710 | RORC | 0.8456 |
| Collecting duct acid secretion_Homo sapiens_hsa04966 | CA2 | 0.8579 |
| Terpenoid backbone biosynthesis_Homo sapiens_hsa00900 | FDPS | 0.9097 |
| Other glycan degradation_Homo sapiens_hsa00511 | GBA2 | 0.9642 |
| Folate biosynthesis_Homo sapiens_hsa00790 | ALPL | 1.0376 |
| Vitamin B6 metabolism_Homo sapiens_hsa00750 | AOX1 | 1.2724 |
Target Exprsssion in Healthy Human Tissues (protein & mRNA level)
Protein expression data was from the "Human Proteome Map" datasetmRNA expression data was from the "GTEx" dataset
Average Target Expression (Fold Change) in Multiple Disease Conditions
Fold Change with Corresponding Normal SamplesClick each cell within the heatmap to access gene expression of individual patient samples